This company has been marked as potentially delisted and may not be actively trading. ContraVir Pharmaceuticals (CTRV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CTRV vs. SLRX, CYCC, EYEN, ADXS, PCSA, RSLS, BPTH, ASLN, VINC, and CWBRShould you be buying ContraVir Pharmaceuticals stock or one of its competitors? The main competitors of ContraVir Pharmaceuticals include Salarius Pharmaceuticals (SLRX), Cyclacel Pharmaceuticals (CYCC), Eyenovia (EYEN), Ayala Pharmaceuticals (ADXS), Processa Pharmaceuticals (PCSA), ReShape Lifesciences (RSLS), Bio-Path (BPTH), ASLAN Pharmaceuticals (ASLN), Vincerx Pharma (VINC), and CohBar (CWBR). These companies are all part of the "medical" sector. ContraVir Pharmaceuticals vs. Salarius Pharmaceuticals Cyclacel Pharmaceuticals Eyenovia Ayala Pharmaceuticals Processa Pharmaceuticals ReShape Lifesciences Bio-Path ASLAN Pharmaceuticals Vincerx Pharma CohBar Salarius Pharmaceuticals (NASDAQ:SLRX) and ContraVir Pharmaceuticals (NASDAQ:CTRV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Which has preferable earnings and valuation, SLRX or CTRV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius PharmaceuticalsN/AN/A-$12.54M-$7.07-0.10ContraVir PharmaceuticalsN/AN/A-$9.45MN/AN/A Which has more risk & volatility, SLRX or CTRV? Salarius Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, ContraVir Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Do insiders and institutionals believe in SLRX or CTRV? 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 1.1% of ContraVir Pharmaceuticals shares are held by institutional investors. 1.4% of Salarius Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of ContraVir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in SLRX or CTRV? ContraVir Pharmaceuticals received 193 more outperform votes than Salarius Pharmaceuticals when rated by MarketBeat users. Likewise, 74.49% of users gave ContraVir Pharmaceuticals an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSalarius PharmaceuticalsOutperform Votes2654.17% Underperform Votes2245.83% ContraVir PharmaceuticalsOutperform Votes21974.49% Underperform Votes7525.51% Is SLRX or CTRV more profitable? Salarius Pharmaceuticals' return on equity of -140.28% beat ContraVir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -140.28% -105.76% ContraVir Pharmaceuticals N/A -4,810.77%-130.14% Does the media refer more to SLRX or CTRV? In the previous week, Salarius Pharmaceuticals had 3 more articles in the media than ContraVir Pharmaceuticals. MarketBeat recorded 3 mentions for Salarius Pharmaceuticals and 0 mentions for ContraVir Pharmaceuticals. ContraVir Pharmaceuticals' average media sentiment score of 0.00 beat Salarius Pharmaceuticals' score of -0.14 indicating that ContraVir Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Salarius Pharmaceuticals Neutral ContraVir Pharmaceuticals Neutral SummaryContraVir Pharmaceuticals beats Salarius Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get ContraVir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTRV vs. The Competition Export to ExcelMetricContraVir PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$258,000.00$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.31%P/E RatioN/A6.9521.9417.82Price / SalesN/A231.01380.9497.68Price / CashN/A65.6738.2634.64Price / Book0.405.936.453.98Net Income-$9.45M$143.22M$3.22B$247.81M ContraVir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTRVContraVir PharmaceuticalsN/A$0.32-6.1%N/A-84.0%$258,000.00N/A0.0014High Trading VolumeSLRXSalarius Pharmaceuticals0.3109 of 5 stars$0.81+12.8%N/A-82.8%$1.40MN/A-0.1020Short Interest ↑News CoverageCYCCCyclacel Pharmaceuticals2.0075 of 5 stars$0.21+13.6%$11.00+5,049.8%-87.4%$1.34M$74,000.00-0.0214Analyst ForecastNews CoverageGap DownEYENEyenovia1.745 of 5 stars$0.92-1.0%$2.00+117.4%-97.6%$1.28M$31,832.00-0.0240ADXSAyala PharmaceuticalsN/A$0.03flatN/AN/A$1.28M$3.24M0.0020Analyst ForecastHigh Trading VolumePCSAProcessa Pharmaceuticals3.3107 of 5 stars$0.24-18.6%$6.00+2,408.4%-86.1%$1.26MN/A-0.0720Gap DownRSLSReShape Lifesciences0.2299 of 5 stars$0.38-12.5%N/A-96.8%$1.25M$8.18M-0.0350Short Interest ↑Gap DownHigh Trading VolumeBPTHBio-Path1.357 of 5 stars$0.15flat$20.00+13,233.3%-96.2%$1.25MN/A0.0010Analyst ForecastGap DownASLNASLAN PharmaceuticalsN/A$0.60flat$72.00+11,900.0%N/A$1.23M$12M-0.0330VINCVincerx Pharma2.4295 of 5 stars$0.54-8.0%$40.00+7,266.5%N/A$1.22MN/A-0.0360Short Interest ↑News CoverageHigh Trading VolumeCWBRCohBarN/A$0.41flatN/AN/A$1.19MN/A0.0010 Related Companies and Tools Related Companies Salarius Pharmaceuticals Competitors Cyclacel Pharmaceuticals Competitors Eyenovia Competitors Ayala Pharmaceuticals Competitors Processa Pharmaceuticals Competitors ReShape Lifesciences Competitors Bio-Path Competitors ASLAN Pharmaceuticals Competitors Vincerx Pharma Competitors CohBar Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTRV) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraVir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTRV Stock Free CTRV Stock Alerts